Stebbing J, Lauschke VM. JAK inhibitors—more than just gluco– corticoids. N Engl J Med 2021;385(5):463–465. DOI: 10.1056/NEJMe2108667.
Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19; N Engl J Med 2021;384(8):693–704. DOI: 10.1056/NEJMoa2021436.
Titanji BK, Farley MM, Mehta A, Connor-Schuler R, Moanna A, Cribbs SK, et al. Use of baricitinib in patients with moderate to severe coronavirus disease-2019. Clin Infect Dis 2021;72(7):1247–1250. DOI: 10.1093/cid/ciaa879.
Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med 2021;384(9):795–807. DOI: 10.1056/NEJMoa2031994.
Satarker S, Tom AA, Shaji RA, Alosious A, Luvis M, Nampoothiri M. Clinical focus: pulmonary and respiratory conditions review. JAK-STAT pathway inhibition and their implications in COVID-19 therapy. Postgrad Med 2021;133(5):489–507. DOI: 10.1080/00325481.2020.1855921.
Guimaraes PO, Quirk D, Furtado RH, Maia LN, Saraiva JF, Antunes MO, et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med 2021;385(5):406–415. DOI: 10.1056/NEJMoa2101643.
Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, et al. Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis 2020:ciaa478. DOI: 10.1093/cid/ciaa478. Available from: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/.
Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol 2020;76(1):122–124. DOI: 10.1016/j.jacc.2020.05.001.
Hayek ME, Mansour M, Ndetan H, Burkes Q, Corkern R, Dulli A, et al. Anti-inflammatory treatment of COVID-19 pneumonia with tofacitinib alone or in combination with dexamethasone is safe and possibly superior to dexamethasone as a single agent in a predominantly African American Cohort. Mayo Clin Proc Innov Qual Outcomes 2021;5(3):605–613. DOI: 10.1016/j.mayocpiqo.2021.03.007.
Fajgenbaum D, June C. Cytokine storm. N Engl J Med 2020;383(23): 2255–2273. DOI: 10.1056/NEJMra2026131.
Patoulias D, Doumas M, Papadopoulos C, Karagiannis A. Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. Clin Rheumatol 2021. DOI: 10.1007/s10067-021-05884-4.
Singh PK, Lalwani LK, Govindagoudar MB, Aggarwal R, Chaudhry D, Kumar P, et al. Tofacitinib Associated with Reduced Intubation Rates in the Management of Severe COVID-19 Pneumonia: A Preliminary Experience. Indian J Crit Care Med 2021;25(10):1106–1110.